mitomycin has been researched along with Appendiceal Cancer in 64 studies
Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study evaluated health-related quality of life (HRQOL) using patient-reported outcomes in subjects with mucinous appendiceal neoplasms who underwent cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) as part of a randomized trial comparing mitomycin with oxaliplatin." | 9.34 | Health-Related Quality of Life After Cytoreductive Surgery/HIPEC for Mucinous Appendiceal Cancer: Results of a Multicenter Randomized Trial Comparing Oxaliplatin and Mitomycin. ( Bartlett, DL; Levine, EA; Mansfield, P; McQuellon, R; Moaven, O; Russell, G; Shen, P; Stewart, JH; Votanopoulos, KI, 2020) |
| "The patients included were 145 who had colorectal or appendiceal carcinomatosis resected using cytoreductive surgery prior to treatment with hyperthermic intraperitoneal chemotherapy with mitomycin C as part of a multidrug regimen." | 7.77 | Changes induced by surgical and clinical factors in the pharmacology of intraperitoneal mitomycin C in 145 patients with peritoneal carcinomatosis. ( Chang, D; Mahteme, H; Stuart, OA; Sugarbaker, PH; Van der Speeten, K, 2011) |
| "Intraperitoneal chemotherapy with mitomycin C and 5-fluorouracil has been used to rescue patients from peritoneal carcinomatosis after perforated cystadenocarcinoma of the large bowel or appendix." | 7.68 | Histologic changes induced by intraperitoneal chemotherapy with 5-fluorouracil and mitomycin C in patients with peritoneal carcinomatosis from cystadenocarcinoma of the colon or appendix. ( Jaffe, G; Landy, D; Pascal, R; Sugarbaker, PH, 1990) |
| "Neutropenia is a frequent complication associated with MMC-HIPEC." | 5.35 | Incidence, risk factors, and impact of severe neutropenia after hyperthermic intraperitoneal mitomycin C. ( Armstrong, TS; Eng, C; Gonzalez-Moreno, S; Katz, MH; Lambert, DH; Lambert, LA; Lee, JJ; Liu, S; Mansfield, PF; Tansey, P; Tortorice, ML; Wolff, RA, 2009) |
| "This study evaluated health-related quality of life (HRQOL) using patient-reported outcomes in subjects with mucinous appendiceal neoplasms who underwent cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) as part of a randomized trial comparing mitomycin with oxaliplatin." | 5.34 | Health-Related Quality of Life After Cytoreductive Surgery/HIPEC for Mucinous Appendiceal Cancer: Results of a Multicenter Randomized Trial Comparing Oxaliplatin and Mitomycin. ( Bartlett, DL; Levine, EA; Mansfield, P; McQuellon, R; Moaven, O; Russell, G; Shen, P; Stewart, JH; Votanopoulos, KI, 2020) |
| "Although peritoneal carcinomatosis (PC) from colorectal and appendiceal tumors is consistent with metastatic disease, complete cytoreduction with hyperthermic intraperitoneal chemotherapy (HIPEC) using mitomycin C (MMC) can improve survival." | 3.79 | A comparison of hematologic toxicity profiles after heated intraperitoneal chemotherapy with oxaliplatin and mitomycin C. ( Ihemelandu, C; Levine, EA; Russell, G; Shen, P; Stewart, J; Votanopoulos, K, 2013) |
| "The patients included were 145 who had colorectal or appendiceal carcinomatosis resected using cytoreductive surgery prior to treatment with hyperthermic intraperitoneal chemotherapy with mitomycin C as part of a multidrug regimen." | 3.77 | Changes induced by surgical and clinical factors in the pharmacology of intraperitoneal mitomycin C in 145 patients with peritoneal carcinomatosis. ( Chang, D; Mahteme, H; Stuart, OA; Sugarbaker, PH; Van der Speeten, K, 2011) |
| "Intraperitoneal chemotherapy with mitomycin C and 5-fluorouracil has been used to rescue patients from peritoneal carcinomatosis after perforated cystadenocarcinoma of the large bowel or appendix." | 3.68 | Histologic changes induced by intraperitoneal chemotherapy with 5-fluorouracil and mitomycin C in patients with peritoneal carcinomatosis from cystadenocarcinoma of the colon or appendix. ( Jaffe, G; Landy, D; Pascal, R; Sugarbaker, PH, 1990) |
| "Appendiceal cancer is a rare disease that has proven difficult to study in prospective trials." | 2.87 | A Multicenter Randomized Trial to Evaluate Hematologic Toxicities after Hyperthermic Intraperitoneal Chemotherapy with Oxaliplatin or Mitomycin in Patients with Appendiceal Tumors. ( Bartlett, D; Fenstermaker, J; Levine, EA; Mansfield, P; Russell, G; Shen, P; Stewart, JH; Votanopoulos, KI, 2018) |
| "The median (range) peritoneal carcinomatosis index was 13 (3-20) requiring a median operative time of 6." | 2.78 | A phase I trial of thermal sensitization using induced oxidative stress in the context of HIPEC. ( Harrison, LE; Razavi, R; Tiesi, G; Wang, CC, 2013) |
| "There were 51 patients with colorectal cancer and 130 patients with appendiceal cancer." | 2.68 | Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. ( Jablonski, KA; Sugarbaker, PH, 1995) |
| "Mucinous appendiceal neoplasms (MANs) are rare tumours and the primary cause of pseudomyxoma peritonei." | 2.66 | Mucinous appendiceal neoplasms with or without pseudomyxoma peritonei: a review. ( Alshahrani, MS; Lansom, J; Morris, DL; Soucisse, ML, 2020) |
| "Management of peritoneal disease from appendiceal neoplasms has historically been with debulking surgery." | 2.61 | Outcomes from cytoreduction and hyperthermic intraperitoneal chemotherapy for appendiceal epithelial neoplasms. ( Craig Lynch, A; Heriot, A; Michael, M; Narasimhan, V; Pham, T; Ramsay, R; Tie, J; Warrier, S, 2019) |
| "Mitomycin-C (MMC) was used in 20% and oxaliplatin in 10%." | 1.56 | Toxicity profile of chemotherapy agents used in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies. ( Ashwin, KR; Kumar C, R; Rauthan, A; Somashekhar, SP; Yethadka, R; Zaveri, S, 2020) |
| " The study is to analyze the incidence of perioperative serious adverse events (SAEs) of CRS + HIPEC to treat PMP patients, and identify the risk factors, for guiding the prevention of SAEs." | 1.56 | Perioperative safety after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei from appendiceal origin: Experience on 254 patients from a single center. ( Chen, LF; Ji, ZH; Li, XB; Li, Y; Lin, YL; Ma, R; Yan, FC; Yang, ZR; Zhang, J, 2020) |
| "Pseudomyxoma peritonei is rare, almost always of appendiceal origin, and presents in various ways relevant to abdominal surgeons." | 1.56 | Mode of Presentation in 1070 Patients With Perforated Epithelial Appendiceal Tumors, Predominantly with Pseudomyxoma Peritonei. ( Cecil, TD; Chandrakumaran, K; Dayal, S; Mohamed, F; Moran, BJ; Shariff, US, 2020) |
| "No recurrent inguinal hernias were recorded and no patients required an inguinal incision at a later time to resect progressive disease within the inguinal canal." | 1.46 | Management of an inguinal hernia in patients with pseudomyxoma peritonei. ( Sugarbaker, PH, 2017) |
| "Mitomycin C has been the most commonly used chemotherapeutic in HIPEC for the past several decades." | 1.46 | Pulmonary toxicity after intraperitoneal mitomycin C: a case report of a rare complication of HIPEC. ( Abel, ML; Blazer, DG; Kokosis, G, 2017) |
| "Conclusions Prophylactic HIPEC for appendiceal neoplasms is feasible, safe and may be performed laparoscopically." | 1.43 | Prophylactic hyperthermic intraperitoneal chemotherapy in patients with epithelial appendiceal neoplasms. ( Aycart, SN; Berger, Y; Hiotis, S; Labow, DM; Sarpel, U; Shtilbans, T; Tuvin, D, 2016) |
| "Mitomycin C (88." | 1.40 | Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: outcomes from a single tertiary institution. ( Hiotis, S; Jibara, G; Labow, DM; Romanoff, A; Sarpel, U; Shrager, B; Tabrizian, P; Yang, MJ, 2014) |
| "Most classifications of mucinous appendiceal neoplasms (MAN) do not take into consideration the type of primary tumor or the burden of peritoneal disease." | 1.40 | Evaluation of a new staging classification and a Peritoneal Surface Disease Severity Score (PSDSS) in 229 patients with mucinous appendiceal neoplasms with or without peritoneal dissemination. ( Esquivel, J; Garcia, SS; Hicken, W; Seibel, J; Shekitka, K; Trout, R, 2014) |
| "Among the CRC and appendiceal cancer group the median overall survival was 20." | 1.40 | [Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis of colorectal and appendiceal origin]. ( Aderka, D; Berger, Y; Brenner, B; Golan, T; Gutman, M; Lebedyev, A; Levi, Y; Natur, M; Nevler, A; Purim, O; Zbar, AP, 2014) |
| "Patients with PC from colorectal or appendiceal cancer, pseudomyxoma peritonei or malignant peritoneal mesothelioma referred to the single national HIPEC centre were prospectively registered from June 2006 to July 2012." | 1.39 | Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: the Danish experience. ( Hagemann-Madsen, R; Iversen, LH; Laurberg, S; Rasmussen, PC, 2013) |
| "Severe obesity is associated with decreased long-term survival only in patients with LGA primary disease; however, application of CRS/HIPEC still offers meaningful prolongation of life." | 1.39 | Obesity and peritoneal surface disease: outcomes after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for appendiceal and colon primary tumors. ( Levine, EA; Randle, RW; Shen, P; Stewart, JH; Swett, KR; Swords, DS; Votanopoulos, KI, 2013) |
| "Neutropenia is a frequent complication associated with MMC-HIPEC." | 1.35 | Incidence, risk factors, and impact of severe neutropenia after hyperthermic intraperitoneal mitomycin C. ( Armstrong, TS; Eng, C; Gonzalez-Moreno, S; Katz, MH; Lambert, DH; Lambert, LA; Lee, JJ; Liu, S; Mansfield, PF; Tansey, P; Tortorice, ML; Wolff, RA, 2009) |
| "Prognosis was poorer for patients with colon cancer, who had a median survival of 7." | 1.32 | Total abdominal colectomy, pelvic peritonectomy, and end-ileostomy for the surgical palliation of mucinous peritoneal carcinomatosis from non-gynecologic cancer. ( Karakozis, S; Stamou, KM; Sugarbaker, PH, 2003) |
| "The outcome of patients with mucinous appendiceal neoplasms with peritoneal surface dissemination has changed as a result of a better understanding of the clinical and pathologic features of this disease." | 1.31 | Second-look surgery in patients with peritoneal dissemination from appendiceal malignancy: analysis of prognostic factors in 98 patients. ( Esquivel, J; Sugarbaker, PH, 2001) |
| "The role in colorectal cancer is less clear, although there are some reports that suggest a benefit." | 1.30 | Peritonectomy and intraperitoneal chemotherapy in appendiceal and colorectal cancer. ( Clingan, P; Horsell, KW; King, DW; Merten, S; Morris, DL, 1999) |
| "Peritoneal carcinomatosis is a treatable condition in selected patients with a possibility for long-term disease-free survival." | 1.29 | Prognostic features for peritoneal carcinomatosis in colorectal and appendiceal cancer patients when treated by cytoreductive surgery and intraperitoneal chemotherapy. ( Chang, D; Koslowe, P; Sugarbaker, PH, 1996) |
| "Peritoneal carcinomatosis has been regarded as a uniformly lethal clinical entity with no specific plan for management." | 1.29 | Treatment of peritoneal carcinomatosis from colon or appendiceal cancer with induction intraperitoneal chemotherapy. ( Sugarbaker, PH, 1996) |
| "Pseudomyxoma peritonei is a rare disease caused by a perforated adenoma of the appendix." | 1.29 | Patterns of failure following treatment of pseudomyxoma peritonei of appendiceal origin. ( Sugarbaker, PH; Zoetmulder, FA, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (12.50) | 18.2507 |
| 2000's | 17 (26.56) | 29.6817 |
| 2010's | 28 (43.75) | 24.3611 |
| 2020's | 11 (17.19) | 2.80 |
| Authors | Studies |
|---|---|
| Ghelardi, F | 1 |
| Raimondi, A | 1 |
| Morano, F | 1 |
| Randon, G | 1 |
| Pannone, A | 1 |
| Guaglio, M | 1 |
| Mazzoli, G | 1 |
| Nasca, V | 1 |
| Milione, M | 1 |
| Leoncini, G | 1 |
| Sabella, G | 1 |
| Greco, GF | 1 |
| Lampis, BR | 1 |
| Galassi, M | 1 |
| Delfanti, S | 1 |
| Nannini, M | 1 |
| Intini, R | 1 |
| Baratti, D | 2 |
| Di Bartolomeo, M | 1 |
| Deraco, M | 2 |
| Pietrantonio, F | 1 |
| Bartlett, K | 1 |
| Derrington, S | 1 |
| Jariwala, N | 1 |
| Mai, C | 1 |
| Koo, B | 1 |
| Somashekhar, SP | 1 |
| Yethadka, R | 1 |
| Kumar C, R | 1 |
| Ashwin, KR | 1 |
| Zaveri, S | 1 |
| Rauthan, A | 1 |
| Moaven, O | 1 |
| Votanopoulos, KI | 3 |
| Shen, P | 5 |
| Mansfield, P | 2 |
| Bartlett, DL | 2 |
| Russell, G | 3 |
| McQuellon, R | 1 |
| Stewart, JH | 4 |
| Levine, EA | 5 |
| Tun, S | 1 |
| Eng, OS | 1 |
| Malec, M | 1 |
| Li, XB | 1 |
| Ma, R | 1 |
| Ji, ZH | 1 |
| Lin, YL | 1 |
| Zhang, J | 1 |
| Yang, ZR | 1 |
| Chen, LF | 1 |
| Yan, FC | 1 |
| Li, Y | 1 |
| Sugarbaker, PH | 18 |
| Soucisse, ML | 1 |
| Lansom, J | 1 |
| Alshahrani, MS | 1 |
| Morris, DL | 4 |
| Shariff, US | 1 |
| Chandrakumaran, K | 5 |
| Dayal, S | 1 |
| Mohamed, F | 5 |
| Cecil, TD | 3 |
| Moran, BJ | 3 |
| Barrak, D | 1 |
| Desale, S | 1 |
| Yoon, JJ | 1 |
| Dugan, MM | 1 |
| Kodavanti, PP | 1 |
| Sampah, ME | 1 |
| Benzaquen, E | 1 |
| Wang, Y | 1 |
| Wiseman, S | 1 |
| Rosenfeld, V | 1 |
| Sideris, L | 3 |
| Dubé, P | 3 |
| Pelletier, JS | 1 |
| Vanounou, T | 1 |
| Zhang, C | 1 |
| Plambeck, BD | 1 |
| Craig, ME | 1 |
| Tu, A | 1 |
| Mikus, RJ | 1 |
| Shostrom, V | 1 |
| McDermott, SP | 1 |
| Igbinigie, I | 1 |
| Brown, K | 1 |
| Cushman-Vokoun, A | 1 |
| Foster, JM | 1 |
| Fenstermaker, J | 1 |
| Bartlett, D | 1 |
| Aziz, O | 1 |
| Jaradat, I | 1 |
| Chakrabarty, B | 1 |
| Selvasekar, CR | 1 |
| Fulford, PE | 1 |
| Saunders, MP | 1 |
| Renehan, AG | 1 |
| Wilson, MS | 1 |
| O'Dwyer, ST | 1 |
| García, KM | 1 |
| Flores, KM | 1 |
| Ruiz, A | 1 |
| González, FL | 1 |
| Rodríguez, ÁM | 1 |
| Narasimhan, V | 1 |
| Pham, T | 1 |
| Warrier, S | 1 |
| Craig Lynch, A | 1 |
| Michael, M | 1 |
| Tie, J | 1 |
| Ramsay, R | 1 |
| Heriot, A | 1 |
| Turner, KM | 1 |
| Hanna, NN | 1 |
| Zhu, Y | 1 |
| Jain, A | 1 |
| Kesmodel, SB | 1 |
| Switzer, RA | 1 |
| Taylor, LM | 1 |
| Richard Alexander, H | 1 |
| Iversen, LH | 1 |
| Rasmussen, PC | 1 |
| Hagemann-Madsen, R | 1 |
| Laurberg, S | 1 |
| Swords, DS | 1 |
| Swett, KR | 1 |
| Randle, RW | 1 |
| Sardi, A | 1 |
| Jimenez, WA | 1 |
| Nieroda, C | 1 |
| Sittig, M | 1 |
| Macdonald, R | 1 |
| Gushchin, V | 2 |
| Fish, R | 1 |
| Selvasekar, C | 1 |
| Crichton, P | 1 |
| Wilson, M | 1 |
| Fulford, P | 1 |
| Renehan, A | 1 |
| O'Dwyer, S | 1 |
| McConnell, YJ | 1 |
| Mack, LA | 2 |
| Gui, X | 1 |
| Carr, NJ | 1 |
| Temple, WJ | 2 |
| Tabrizian, P | 1 |
| Shrager, B | 1 |
| Jibara, G | 1 |
| Yang, MJ | 1 |
| Romanoff, A | 1 |
| Hiotis, S | 2 |
| Sarpel, U | 2 |
| Labow, DM | 2 |
| Esquivel, J | 3 |
| Garcia, SS | 1 |
| Hicken, W | 1 |
| Seibel, J | 1 |
| Shekitka, K | 1 |
| Trout, R | 1 |
| Berger, Y | 2 |
| Zbar, AP | 1 |
| Lebedyev, A | 1 |
| Levi, Y | 1 |
| Nevler, A | 1 |
| Aderka, D | 1 |
| Golan, T | 1 |
| Purim, O | 1 |
| Brenner, B | 1 |
| Natur, M | 1 |
| Gutman, M | 1 |
| Lord, AC | 1 |
| Shihab, O | 1 |
| Sparks, DS | 1 |
| Morris, B | 1 |
| Xu, W | 1 |
| Fulton, J | 1 |
| Atkinson, V | 1 |
| Meade, B | 1 |
| Lutton, N | 1 |
| Moran, B | 2 |
| Cecil, T | 2 |
| Arnold, S | 1 |
| Venkatasubramaniam, A | 1 |
| Sabourin, JC | 1 |
| Tuvin, D | 1 |
| Aycart, SN | 1 |
| Shtilbans, T | 1 |
| Di Fabio, F | 1 |
| Mehta, A | 1 |
| Abel, ML | 1 |
| Kokosis, G | 1 |
| Blazer, DG | 1 |
| Lanuke, K | 1 |
| Mitchell, A | 1 |
| Drolet, P | 1 |
| Leblanc, G | 1 |
| Leclerc, YE | 1 |
| Lambert, LA | 2 |
| Armstrong, TS | 1 |
| Lee, JJ | 1 |
| Liu, S | 1 |
| Katz, MH | 1 |
| Eng, C | 1 |
| Wolff, RA | 1 |
| Tortorice, ML | 1 |
| Tansey, P | 1 |
| Gonzalez-Moreno, S | 3 |
| Lambert, DH | 1 |
| Mansfield, PF | 2 |
| Van der Speeten, K | 1 |
| Stuart, OA | 1 |
| Chang, D | 4 |
| Mahteme, H | 1 |
| Austin, F | 1 |
| Mavanur, A | 1 |
| Sathaiah, M | 1 |
| Steel, J | 1 |
| Lenzner, D | 1 |
| Ramalingam, L | 1 |
| Holtzman, M | 1 |
| Ahrendt, S | 1 |
| Pingpank, J | 1 |
| Zeh, HJ | 1 |
| Choudry, HA | 1 |
| Votanopoulos, K | 1 |
| Ihemelandu, C | 1 |
| Stewart, J | 1 |
| Klaver, YL | 1 |
| Chua, TC | 1 |
| Verwaal, VJ | 1 |
| de Hingh, IH | 1 |
| Harrison, LE | 1 |
| Tiesi, G | 1 |
| Razavi, R | 1 |
| Wang, CC | 1 |
| Stamou, KM | 1 |
| Karakozis, S | 1 |
| Brun, E | 1 |
| Alderman, R | 1 |
| Edwards, G | 1 |
| Marquardt, CE | 1 |
| Yan, TD | 2 |
| Links, M | 1 |
| Xu, ZY | 1 |
| Kam, PC | 1 |
| Glenn, D | 1 |
| Bijelic, L | 1 |
| McQuellon, RP | 2 |
| Russell, GB | 2 |
| Saunders, W | 1 |
| Kusamura, S | 1 |
| Nonaka, D | 1 |
| Langer, M | 1 |
| Andreola, S | 1 |
| Favaro, M | 1 |
| Gavazzi, C | 1 |
| Laterza, B | 1 |
| Jablonski, KA | 1 |
| Koslowe, P | 1 |
| Zoetmulder, FA | 1 |
| Hosch, WP | 1 |
| Rudi, J | 1 |
| Stremmel, W | 1 |
| Horsell, KW | 1 |
| Merten, S | 1 |
| Clingan, P | 1 |
| King, DW | 1 |
| Sasaki, A | 1 |
| Terashima, M | 1 |
| Okamoto, K | 1 |
| Ikeda, K | 1 |
| Takagane, A | 1 |
| Takiyama, I | 1 |
| Shimada, Y | 1 |
| Yamamoto, M | 1 |
| Nakajima, J | 1 |
| Sasaki, N | 1 |
| Saito, K | 1 |
| Loggie, BW | 1 |
| Fleming, RA | 1 |
| Geisinger, KR | 1 |
| Landy, D | 1 |
| Jaffe, G | 1 |
| Pascal, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Diagnostic Value of Diffusion-weighted Magnetic Resonance Imaging for Detection of Peritoneal Recurrence in Patients With High-risk Colorectal and Appendiceal Neoplasms : a Pilot Study[NCT05623787] | 30 participants (Anticipated) | Interventional | 2022-09-01 | Recruiting | |||
| A Phase II Trial to Analyze Clinical and Pharmacological Properties for Severe Neutropenia After Cytoreductive Surgery Followed by Hyperthermic Intraperitoneal Chemotherapy Using Mitomycin-C[NCT05513183] | 74 participants (Actual) | Observational | 2021-05-20 | Completed | |||
| Thrombin Generation and Platelet Activation in Cytoreductive Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy[NCT03034850] | 27 participants (Actual) | Observational | 2015-04-30 | Completed | |||
| Pathophysiology of Inflammation After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy[NCT02741167] | 90 participants (Anticipated) | Observational | 2016-01-31 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for mitomycin and Appendiceal Cancer
| Article | Year |
|---|---|
Mucinous appendiceal neoplasms with or without pseudomyxoma peritonei: a review.
Topics: Appendiceal Neoplasms; Cytoreduction Surgical Procedures; Humans; Hyperthermia, Induced; Mitomycin; | 2020 |
Appendiceal tumors with glandular and neuroendocrine features exhibiting peritoneal metastases - Critical evaluation of outcome following cytoreductive surgery with perioperative chemotherapy.
Topics: Adenocarcinoma; Administration, Intravenous; Adult; Aged; Antineoplastic Combined Chemotherapy Proto | 2021 |
Pseudomyxoma Peritonei: Case Report and Literature Review.
Topics: Appendiceal Neoplasms; Appendix; Biopsy; Colectomy; Combined Modality Therapy; Cytoreduction Surgica | 2019 |
Outcomes from cytoreduction and hyperthermic intraperitoneal chemotherapy for appendiceal epithelial neoplasms.
Topics: Antibiotics, Antineoplastic; Appendiceal Neoplasms; Australia; Chemotherapy, Cancer, Regional Perfus | 2019 |
[Peritoneal tumor pathology: case n(o) 2: a "sticky" peritoneal tumor].
Topics: Abdominal Pain; Adult; Antineoplastic Agents, Alkylating; Appendectomy; Appendiceal Neoplasms; Combi | 2015 |
New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome?
Topics: Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Combined Modality Therapy; Fl | 2006 |
8 trials available for mitomycin and Appendiceal Cancer
| Article | Year |
|---|---|
Health-Related Quality of Life After Cytoreductive Surgery/HIPEC for Mucinous Appendiceal Cancer: Results of a Multicenter Randomized Trial Comparing Oxaliplatin and Mitomycin.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Appendiceal Neoplas | 2020 |
A Multicenter Randomized Trial to Evaluate Hematologic Toxicities after Hyperthermic Intraperitoneal Chemotherapy with Oxaliplatin or Mitomycin in Patients with Appendiceal Tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Appendectomy; Appendiceal Neoplasms; Blood Ce | 2018 |
Risk-reducing laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for low-grade appendiceal mucinous neoplasm: early outcomes and technique.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Appendiceal Neoplasms; Combined Modality Therapy; Drug Admini | 2014 |
Phase II study of regional treatment for peritoneal carcinomatosis.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Appendiceal Neoplasms; Chemotherapy, Cancer, R | 2009 |
Secondary cytoreductive surgery and peri-operative intraperitoneal chemotherapy for peritoneal recurrence of colorectal and appendiceal peritoneal carcinomatosis following prior primary cytoreduction.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Appendiceal Neoplasms; Chemotherapy, Adjuvant; Chemoth | 2013 |
A phase I trial of thermal sensitization using induced oxidative stress in the context of HIPEC.
Topics: Adult; Aged; Antineoplastic Agents; Appendiceal Neoplasms; Carcinoma; Colonic Neoplasms; Female; Hum | 2013 |
Cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei from appendiceal mucinous neoplasms.
Topics: Adenocarcinoma, Mucinous; Adult; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplas | 2006 |
Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Appendicea | 1995 |
50 other studies available for mitomycin and Appendiceal Cancer
| Article | Year |
|---|---|
Mytomicin-C, Metronomic Capecitabine, and Bevacizumab in Patients With Unresectable or Relapsed Pseudomyxoma Peritonei of Appendiceal Origin.
Topics: Appendiceal Neoplasms; Bevacizumab; Capecitabine; Disease Progression; Humans; Hyperthermia, Induced | 2023 |
Scrotal ulceration: a complication of hyperthermic intraperitoneal chemotherapy and subsequent treatment with dimethyl sulfoxide.
Topics: Adenocarcinoma; Administration, Cutaneous; Antibiotics, Antineoplastic; Appendiceal Neoplasms; Dimet | 2019 |
Toxicity profile of chemotherapy agents used in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neop | 2020 |
Health-Related Quality of Life After Cytoreductive Surgery/HIPEC for Mucinous Appendiceal Cancer: Results of a Multicenter Randomized Trial Comparing Oxaliplatin and Mitomycin.
Topics: Appendiceal Neoplasms; Cytoreduction Surgical Procedures; Humans; Hyperthermia, Induced; Mitomycin; | 2020 |
Perioperative safety after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei from appendiceal origin: Experience on 254 patients from a single center.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasm | 2020 |
Peritoneal carcinomatosis of unknown primary site, a study of 25 patients over 30 years.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; | 2020 |
Mode of Presentation in 1070 Patients With Perforated Epithelial Appendiceal Tumors, Predominantly with Pseudomyxoma Peritonei.
Topics: Adenocarcinoma, Mucinous; Aged; Antibiotics, Antineoplastic; Appendiceal Neoplasms; Appendicitis; Bi | 2020 |
Morbidity associated with the use of oxaliplatin versus mitomycin C in hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal or appendiceal origin: a multi-institutional comparative study.
Topics: Adult; Aged; Antineoplastic Agents; Appendiceal Neoplasms; Colorectal Neoplasms; Female; Humans; Hyp | 2021 |
Exploring the prognostic and therapeutic utility of expanded mutation profiling in appendix peritoneal metastasis managed with CRS/HIPEC.
Topics: Adult; Aged; Aged, 80 and over; Appendiceal Neoplasms; Combined Modality Therapy; Cytoreduction Surg | 2021 |
Discussion.
Topics: Appendiceal Neoplasms; Humans; Hyperthermia, Induced; Mitomycin; Oxaliplatin | 2018 |
Predicting Survival After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Appendix Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Appendiceal Neoplasms; Colectomy; Cytoredu | 2018 |
Assessment of neoadjuvant chemotherapy on operative parameters and outcome in patients with peritoneal dissemination from high-grade appendiceal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2013 |
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: the Danish experience.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Appendiceal Neoplasms; Carcinoma; Colorectal Neoplasms; Co | 2013 |
Obesity and peritoneal surface disease: outcomes after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for appendiceal and colon primary tumors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Appendic | 2013 |
Repeated cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from appendiceal cancer: analysis of survival outcomes.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Carboplatin; Car | 2013 |
Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: an emerging treatment option for advanced goblet cell tumors of the appendix.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Appendiceal Neoplasms; Carcinoembryonic Antigen; Carcin | 2014 |
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: outcomes from a single tertiary institution.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Blood Transfusio | 2014 |
Evaluation of a new staging classification and a Peritoneal Surface Disease Severity Score (PSDSS) in 229 patients with mucinous appendiceal neoplasms with or without peritoneal dissemination.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Alkylating Agents; Appendectomy; Appendiceal Neoplasms; Chemo | 2014 |
[Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis of colorectal and appendiceal origin].
Topics: Antibiotics, Antineoplastic; Antineoplastic Protocols; Appendiceal Neoplasms; Carcinoma; Chemotherap | 2014 |
Recurrence and outcome after complete tumour removal and hyperthermic intraperitoneal chemotherapy in 512 patients with pseudomyxoma peritonei from perforated appendiceal mucinous tumours.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Appendiceal Neoplas | 2015 |
Cytoreductive surgery and heated intraperitoneal chemotherapy for peritoneal carcinomatosis secondary to mucinous adenocarcinoma of the appendix.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antibiotics, Antineoplastic; Appendiceal Neoplasms; Chemother | 2015 |
The results of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in 1200 patients with peritoneal malignancy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Cisplatin; Colorectal Neoplas | 2015 |
Prophylactic hyperthermic intraperitoneal chemotherapy in patients with epithelial appendiceal neoplasms.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Appendiceal Neoplasms; Chemotherapy, Cancer, Regional Perf | 2016 |
Advanced Pseudomyxoma Peritonei Requiring Gastrectomy to Achieve Complete Cytoreduction Results in Good Long-Term Oncologic Outcomes.
Topics: Aged; Antibiotics, Antineoplastic; Appendiceal Neoplasms; CA-125 Antigen; CA-19-9 Antigen; Carcinoem | 2016 |
Management of an inguinal hernia in patients with pseudomyxoma peritonei.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appendiceal N | 2017 |
Pulmonary toxicity after intraperitoneal mitomycin C: a case report of a rare complication of HIPEC.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Chemotherapy, Cancer, | 2017 |
Surgical cytoreduction and intraperitoneal chemotherapy for peritoneal carcinomatosis arising from the appendix.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Agents; Appendiceal Neoplasms; Camptothecin; C | 2009 |
Incidence, risk factors, and impact of severe neutropenia after hyperthermic intraperitoneal mitomycin C.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Appendiceal Neoplasms; Combined Modality Therapy; Female; | 2009 |
Changes induced by surgical and clinical factors in the pharmacology of intraperitoneal mitomycin C in 145 patients with peritoneal carcinomatosis.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Ap | 2011 |
Aggressive management of peritoneal carcinomatosis from mucinous appendiceal neoplasms.
Topics: Adenocarcinoma, Mucinous; Antibiotics, Antineoplastic; Appendiceal Neoplasms; Disease-Free Survival; | 2012 |
A comparison of hematologic toxicity profiles after heated intraperitoneal chemotherapy with oxaliplatin and mitomycin C.
Topics: Adult; Antineoplastic Agents; Appendiceal Neoplasms; Blood Platelets; Colorectal Neoplasms; Combined | 2013 |
A comparison of hematologic toxicity profiles after heated intraperitoneal chemotherapy with oxaliplatin and mitomycin C.
Topics: Adult; Antineoplastic Agents; Appendiceal Neoplasms; Blood Platelets; Colorectal Neoplasms; Combined | 2013 |
A comparison of hematologic toxicity profiles after heated intraperitoneal chemotherapy with oxaliplatin and mitomycin C.
Topics: Adult; Antineoplastic Agents; Appendiceal Neoplasms; Blood Platelets; Colorectal Neoplasms; Combined | 2013 |
A comparison of hematologic toxicity profiles after heated intraperitoneal chemotherapy with oxaliplatin and mitomycin C.
Topics: Adult; Antineoplastic Agents; Appendiceal Neoplasms; Blood Platelets; Colorectal Neoplasms; Combined | 2013 |
Third look surgery and beyond for appendiceal malignancy with peritoneal dissemination.
Topics: Adenocarcinoma, Mucinous; Adult; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplas | 2003 |
Total abdominal colectomy, pelvic peritonectomy, and end-ileostomy for the surgical palliation of mucinous peritoneal carcinomatosis from non-gynecologic cancer.
Topics: Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasm | 2003 |
Re: Verwaal VJ, van Tinteren H, Ruth SV, et al.: Toxicity of cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy. J Surg Oncol 2004; 85:61-67.
Topics: Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Chemotherapy, Adjuvant; Color | 2004 |
Lymph node metastasis in epithelial malignancies of the appendix with peritoneal dissemination does not reduce survival in patients treated by cytoreductive surgery and perioperative intraperitoneal chemotherapy.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Combine | 2005 |
An instrument to provide containment of intraoperative intraperitoneal chemotherapy with optimized distribution.
Topics: Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Cisplatin; Containment of Bio | 2005 |
Prospective morbidity and mortality assessment of cytoreductive surgery plus perioperative intraperitoneal chemotherapy to treat peritoneal dissemination of appendiceal mucinous malignancy.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appendiceal N | 2006 |
Interstitial pneumonitis: an exceptional toxicity of hyperthermic intraperitoneal mitomycin C.
Topics: Antibiotics, Antineoplastic; Appendiceal Neoplasms; Female; Humans; Hyperthermia, Induced; Infusions | 2008 |
Critical analysis of treatment failure after complete cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal dissemination from appendiceal mucinous neoplasms.
Topics: Adenocarcinoma, Mucinous; Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Appen | 2007 |
Survival and health outcomes after cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for disseminated peritoneal cancer of appendiceal origin.
Topics: Activities of Daily Living; Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplas | 2008 |
Pseudomyxoma peritonei: clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antibiotics, Antineoplastic; Appendiceal Neoplasms; Biomarker | 2008 |
Prognostic features for peritoneal carcinomatosis in colorectal and appendiceal cancer patients when treated by cytoreductive surgery and intraperitoneal chemotherapy.
Topics: Appendiceal Neoplasms; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Humans | 1996 |
Treatment of peritoneal carcinomatosis from colon or appendiceal cancer with induction intraperitoneal chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Appendiceal Neoplasms; Colonic Neoplasms; Female; Fluorouracil; | 1996 |
Patterns of failure following treatment of pseudomyxoma peritonei of appendiceal origin.
Topics: Abdomen; Adult; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Chemotherapy, | 1996 |
Therapy of pseudomyxoma peritonei of appendiceal origin--surgical resection and intraperitoneal chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Chemotherapy, Ad | 1999 |
Peritonectomy and intraperitoneal chemotherapy in appendiceal and colorectal cancer.
Topics: Abscess; Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; | 1999 |
[Intraperitoneal administration of a combined CDDP, 5-FU and MMC therapy for pseudomyxoma peritonei].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Appendectomy; Appendiceal Neoplasms; Cisplati | 1999 |
Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for disseminated peritoneal cancer of gastrointestinal origin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Appendiceal Neoplasms; Chem | 2000 |
Second-look surgery in patients with peritoneal dissemination from appendiceal malignancy: analysis of prognostic factors in 98 patients.
Topics: Adenocarcinoma, Mucinous; Appendiceal Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; | 2001 |
Histologic changes induced by intraperitoneal chemotherapy with 5-fluorouracil and mitomycin C in patients with peritoneal carcinomatosis from cystadenocarcinoma of the colon or appendix.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Colonic Neoplasm | 1990 |